4 Min Read
(For faster updates on individual market-movers, Eikon users please use search string "STXBZ US"; for the Day Ahead newsletter, link.reuters.com/mex49s; for the Morning News Call newsletter, link.reuters.com/nex49s) U.S. stock index e-mini futures were up on Monday: Dow Jones industrial average futures were up 0.38 percent at 17,796, S&P 500 futures were up 0.41 percent at 2,058.25 and Nasdaq 100 futures were up 0.35 percent at 4,324.
** TESLA MOTORS INC, Friday close $188.68, +2.01 pct premarket
The electric car maker will present a software update to its Model S vehicle at a news conference on Thursday that is designed to quell fears that drivers will run out of power for their cars, Chief Executive Elon Musk said on Sunday.
** BLACKBERRY LTD, Friday close $9.81
Seeking to extend its range of secure mobile devices, BlackBerry Ltd said on Saturday it was launching a high-security tablet, developed with International Business Machines Corp and Samsung Electronics Co Ltd .
** ROYAL DUTCH SHELL, Friday close $57.26, +0.56 pct premarket
Royal Dutch Shell is pulling back from its shale projects in South Africa due to lower energy prices although it is still seeking an exploration license for the onshore Karoo Basin, its country manager said on Monday.
** BOEING CO, Friday close $151.57
The world's biggest planemaker is well-positioned to hit record production targets for its popular 737 jetliner by 2018, having learned from past mistakes, the head of its industrial system told Reuters.
** BARRICK GOLD CORP, Friday close $10.6, +0.57 pct premarket
The Canadian miner may put its Chilean copper mine on the block as the company tries to meet an ambitious debt reduction target, the Financial Times reported.
** ASTRAZENECA PLC, Friday close $67.35, +0.39 pct premarket
New clinical trial results with AstraZeneca's heart drug Brilinta are positive but bleeding risks suggest the company's sales force still has its work cut out to get the medicine widely adopted for long-term use. AstraZeneca is relying on Brilinta, which it believes can sell $3.5 billion annually by 2023, to help offset a wave of patent losses on older drugs.
** ENDO INTERNATIONAL PLC, Friday close $87.33
** VALEANT PHARMACEUTICALS INTERNATIONAL INC, Friday close $197.43
** SALIX PHARMACEUTICALS LTD, Friday close $169.4
Endo, which is in a bidding war with Valeant Pharmaceuticals International Inc for Salix, believes it could close a takeover within as little as five weeks of a negotiated deal, according to an email obtained by Reuters. The timing is possible because under Irish law, there is only a minimum of 17 days required between mailing proxy materials and holding a shareholder meeting, according to the email from Endo Chief Executive Officer Rajiv De Silva to employees.
** MEDTRONIC PLc, Friday close $76.47
Patients treated with the company's CoreValve non-invasive heart valve replacement system fared better two years after the procedure than those who underwent surgical valve replacement, according to data from a study presented on Sunday.
** EDWARDS LIFESCIENCES CORP, Friday close $135.35
Researchers on Sunday presented trial data showing very low mortality and stroke rates using the third generation version of Edwards' non-invasive heart valve replacement system that could help support its U.S. approval.
** MERCK & CO INC, Friday close $56.2
Merck said it expects its long-delayed drug to reverse the effects of anesthesia to be denied U.S. approval after U.S. regulators said they need to conduct more site inspections related to a study of the drug.
** HANESBRANDS INC, Friday close $32.61, +1.90 pct premarket
** AVON PRODUCTS INC, Friday close $7.72
Hanesbrands will replace Avon in the S&P 500 after the close on March 20, S&P Dow Jones Indices said on Friday.
Compiled by Kshitiz Goliya; Editing by Sriraj Kalluvila